Tabernero, J., Chiorean, E. G., Infante, J. R., Hingorani, S. R., Ganju, V., Weekes, C., . . . Von Hoff, D. D. (2015). Prognostic Factors of Survival in a Randomized Phase III Trial (MPACT) of Weekly nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone in Patients With Metastatic Pancreatic Cancer. Oncologist.
Citação norma ChicagoTabernero, Josep, et al. "Prognostic Factors of Survival in a Randomized Phase III Trial (MPACT) of Weekly Nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone in Patients With Metastatic Pancreatic Cancer." Oncologist 2015.
Citação norma MLATabernero, Josep, et al. "Prognostic Factors of Survival in a Randomized Phase III Trial (MPACT) of Weekly Nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone in Patients With Metastatic Pancreatic Cancer." Oncologist 2015.